

Using Cells for Healing

OTCQB: REPCF | TSXV: RP | FRA:P6P2

A Revolution in Sports Medicine and Aesthetics.

We are a regenerative medicine company with innovative cell therapy technology providing unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.

Three applications, two biologics, one game-changing delivery platform

RCS-01:

NBDS Fibroblast Therapy for Aging and Sun-Damaged Skin

RCH-01:

DSC Cell Therapy for Androgenetic Alopecia

AESTHETICS

RCT-01 Tendon Repair (Partnered with YOFOTO

(Partnered with YOFOTO in Greater China; active licensing discussions in Japan)

RCS-01 Dermal Rejuvenation

(Partnered with YOFOTO in Greater China; active licensing discussions in Japan)

RCH-01 Pattern Baldness

(Partnered with Shisiedo in Asia)

POSITIVE PHASE CLINICAL DATA

Randomized (3:1) double-blind, placebo-controlled trial at UBC Sports Medicine Clinic (8 participants)

Primary Endpoint: Safety

Secondary Endpoint: Efficacy at 6 months (function, pain, regeneration, blood flow)

POSITIVE PHASE 1 CLINICAL DATA

Phase 1/2 randomized, double-blinded, placebocontrolled trial at IUF Leibniz-Institut für umweltmedizinische Forschung (Germany)

Primary Endpoint: Safety


Secondary Endpoint: Efficacy at 6 months (biomarkers related so collagen & skin health)

POSITIVE PHASE 1 CLINICAL DATA PIVOTAL STUDY IN JAPAN (ongoing)

Data expected 2H 2018; Potential Japanese market launch 2019, Managed and Funded by

Shiseido.

Primary Endpoint: Hair Density



NBDS Fibroblast

Chronic Tendinosis

Therapy for



RCI-02:

Dermal

Injector Device

The RCI-02 dermal injector is designed to deliver cells, dermal fillers, drug and biologics.

- Digital controls program for depth, volume, rate of dispersion
- Provides exact repeatable dispersion across 3 dimensions
- Removes human variability
- Built-in Peltier element reduces need for anesthetics
- Near-term commercial launch





Poised for growth and momentum

Potential to Revolutionize Sports Medicine and Aesthetics

This innovative cell therapy technology has the potential to revolutionize two large consumer-pay markets where few solutions exist.

The Only Regenerative Medicine Company Using Hair Follicle Cell Therapy

We are the only Company using cells derived from hair follicles to potentially heal damaged skin and tendon tissue—offering hope for people with conditions beyond repair.

Multiple Assets Addressing Conditions With Unmet Need

Multi-product portfolio diversifies risk over several programs in two different markets.

Near-Term Commercial Launch And Revenue Catalysts

Anticipated approval to commercially launch the dermal injector in Europe and Hong Kong by mid-2020 in Europe and Hong Kong. Hair regrowth product could be launched in Japanese market by Shiseido as early as 2020.

Multiple Assets Across Large Market Applications with Key Partnership in Place

Positive phase I clinical data and dermal injector prototypes focused on skin, tendon and hair health (all large markets).

Management Is Commercially-Focused And Strategic

Focus is on levaraging partnership programs and preparing for commercial product launch.

Capital Structure (as at May 2019)

Current market cap. (approx.)	~\$10M
Total money raised through equity to-date	~\$34M
Total revenue to-date (upfront licensing payments)	\$4.24M
Current Monthly Burn Rate	~\$259,000
Shares Issued and Outstanding (Basic/FD)	27.6M / 33.5M

Board and Management Team

David Hal	l
Chairman	

Directors:

Peter Lowry

Andrew Schutte

Peter Lewis

Lee Buckler

Larissa Huang

R. Lee Buckler, B. Ed, LLB President, CEO & Director

Dr. Rolf Hoffman, MDChief Medical Officer

Dr. Kevin McElwee, PhD Chief Scientific Officer

Simon Ma CA
Chief Financial Officer

Petra Goessens-Rueck, DVM

Head of Clinical and Regulatory Affairs